Yissum
Research Development Company


 


of
the Hebrew University of Jerusalem


 


Edmond
Safra Campus,


 


Givat
Ram, POB 39135


 


Jerusalem
91390


 


Israel


 


Re:
Second Extension of Agreement for rendering of Services


 


We
do hereby refer to the Agreement for the Rendering of Services dated as of June 20, 2005 (the "Service Agreement")
and the extension thereto dated as of June 2006 ("Extension of Agreement for Rendering of Services") (jointly
with the Services Agreement, the "Extended Service Agreement") and the License Agreement dated November 27th,
2002 (the "License Agreement") all executed by and between Yissum Research Development Company of the Hebrew University
of Jerusalem ("Yissum") and Morria Biopharmaceuticals, Inc. (the "Company").


 


Unless
the context otherwise requires, all capitalized terms used herein shall have the meaning ascribed to them in the Service Agreement.


 


The
Company does hereby request that, further to Yissum tasks and services pursuant to the Extended Service Agreement, Yissum performs
the additional tasks and services set forth on Appendix A hereto (the "Additional Services"). All of such Additional
Services shall be included in the scope of the definition of Services under the Service Agreement, and shall be performed in accordance
with the timetable set forth on Appendix A hereto. In consideration, the Company shall pay Yissum an additional amount, of $ 40,500
(plus VAT) (the "Additional Service Fee") payable within seven days of the signing of this Letter of Extension.


 


All
terms and conditions as set out in the Service Agreement shall apply mutatis mutandis in respect of the Additional Service
Fee and the Additional Services as defined under this Second Extension of Agreement for Rendering of Services, including without
limitation, the extension of the right and license to the Company of the Service Agreement Results, such to include the Additional
Services (as defined herein).


 


Your
signature on this copy of the document shall constitute your approval and agreement to all that is written herein.


 



    	1



    	 



    

 


	Yours sincerely,	 	 
	 	 	 
	MORRIA BIOPHARMACEUTICALS PLC.	 	 
	/s/ YUVAL COHEN	 	 
	 	 	 	 
	By:
Yuval Cohen, Managing Director, Morria	 	 
	 	 	 
	We
hereby agree and approve:	 	 
	/s/ ELENA CANETTI	 	 
	 	 	 	 
	By: Elena Canetti, VP Scientific Services, Yissum	 	Date: December 19, 2006
	 	 	 
	/s/ NAVA SWERSKY SOFER	 	 
	 	 	 	 
	 	 	 
	 By: Nava Swersky Sofer, CEO, Yissum	 	Date: December 19, 2006 


  



    	2



    	 



    

 


APPENDIX
A


 


Research
Program for Morria Biopharmaceuticals Plc


 


Proposed
by Prof. Saul Yedgar of

the Hebrew University Medical School, Jerusalem


 


Aim:
Development of analytical methods for characterization of MFAIDs and their stability. 


 


Scope


 


		1.	Monitoring of HyPE temporal stability in different solvents,
including 0.lmM and 0.2 mM NaN03, PBS, Na Glutarate, NaCitrate, following filter-sterilization, and storing at room temperature
and 4°C, using



 


		A.	Visocisty (Ostwald capillary viscometers).



 


		B.	Dynamic light scattering (DSL), which will also be used for analyzing
the size distribution of HyPE population into multi-molecular organizations, and its changes during the storage period.



	 	 	 
		2.	Testing
                                                                                                                   of validation
                                                                                                                   methods for
                                                                                                                   HyPE concentration
                                                                                                                   in solutions:
	 	 	 
	 	 	HyPE
solutions, at a wide range of concentrations, will be prepared by the conventional method of dissolving weighted amounts in solvents,
using three analytical balances. The solutions will be subjected to determination by other physico-chemical methods, in order to
prepare corresponding standard curves.


Method to be examined:


Viscosity.


 


Colorimetric
determination of Optical density (spectrophotometry), Dynamic light Scattering.


 


Density
determination by Sound velocity or pycnometry, Elemental analysis.






  


		3.	Testing of MFAID candidates for their potential in treating inflammatory
conditions (inter alia IBD Alzheimer, ALS, cystic fibrosis, arthritis, cancer, stenosis/restenosis, atherosclerosis, Malaria).



 


Duration:
6 months with report to Morria upon request and at the end of period.


Budget:
$40,500 total (including overhead).


 



    	3